[1]Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005, 26(4): 292-297.[2]Moody JA. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. Washington DC: American Society for Microbiology, 1992:22.[3]文亚坤, 曹萌, 邹琳, 等. 碳青霉烯类抗生素耐药铜绿假单胞菌的体外联合药敏研究. 中国抗生素杂志, 2012, 37(7): 536-538.[4]Rey-Jurado E, TudóG, de la Bellacasa JP, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents, 2013, 41(3): 278-280.[5]Rosenblatt JE, Stewart PR. Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli. Antimicrob Agents Chemother, 1974, 6(1): 84-92.[6]Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis, 1978, 137(2): 122-130.[7]Yu VL, Felegie TP, Yee RB, et al. Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. J Infect Dis, 1980, 142(4): 602-607.[8]Yoon J, Urban C, Terzian C, et al. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, 2004, 48(3): 753-757.[9]Cetin ES, Tekeli A, Ozseven AG, et al. Determination of In Vitro Activities of Polymyxin B and Rifampin in Combination with Ampicillin/Sulbactam or Cefoperazone/Sulbactam against Multidrug-Resistant Acinetobacter baumannii by the E-test and Checkerboard Methods. Jpn J Infect Dis, 2013, 66(6): 463-468.[10]Cavalieri SJ, Biehle JR, Sanders WE Jr. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1995, 39(7): 1542-1545.[11]Bergmann JS, Woods GL. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis, 1998, 2(8): 621-626.[12]Bhusal Y,Shioshira CM,Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.Int J Antimicrob Agents,2005,26(4):292-297.[13]Rey-Jurado E, Tudó G, Martínez JA, et al. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis. Tuberculosis (Edinb),2012, 92(3): 260-263.[14]Caleffi-Ferracioli KR, Maltempe FG, Siqueira VL, et al. Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method. Tuberculosis (Edinb), 2013, 93(6): 660-663.[15]Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise,and prospects for the future. J Infect Dis, 2012,205(Suppl 2):S 241-249.[16]Kaur D, Khuller GK. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria. Int J Antimicrob Agents, 2001, 17(1): 51-55.[17]De Logu A, Onnis V, Saddi B, et al. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother, 2002, 49(2): 275-282.[18]Rodriguez Díaz JC, Ruiz M, Lopez M, et al. Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2003, 21(4): 354-356.[19]Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005, 26(4): 292-297.[20]de Steenwinkel JE, de Knegt GJ, ten Kate MT, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother, 2010, 65(12): 2582-2589.[21]Sala C, Hartkoorn RC. Tuberculosis drugs: new candidates and how to find more. Future Microbiol, 2011, 6(6): 617-633.[22]Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis, 2003,7(1):6-21. |